Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Cetiedil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.39 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.39 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.38 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.35 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.34 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cetiedil SCHEMBL14169136 | 0.89 | CYP3A4 (0.44) | CYP3A4CYP1A2CYP2D6TSHRTP53 | |
| Cetiedil SCHEMBL458084 | 0.89 | CYP3A4 (0.44) | CYP3A4CYP1A2CYP2D6TSHRTP53 | |
| Cetiedil SCHEMBL5149883 | 0.80 | C3AR1 (0.42) | CYP3A4CYP1A2CYP2D6TSHRTP53 | |
| SCHEMBL11366829 | 0.72 | SLC6A3 (0.48) | CYP3A4CYP1A2CYP2D6TSHROPRM1 | |
| SCHEMBL8975472 | 0.72 | TP53 (0.72) | CYP3A4CYP1A2CYP2D6TSHRTP53 | |
| Citric Acid SCHEMBL8478591 | 0.71 | PSMB1 (0.61) | ESR1ESR2ALDH1A1 | |
| SCHEMBL14862650 | 0.71 | SLC6A3 (0.46) | CYP3A4CYP1A2CYP2D6TSHROPRM1 | |
| SCHEMBL17111285 | 0.70 | KMT2A (0.49) | CYP3A4CYP1A2CYP2D6TSHRTP53 | |
| SCHEMBL11368109 | 0.70 | SLC6A3 (0.58) | CYP3A4CYP1A2CYP2D6TSHRTP53 | |
| SCHEMBL11147057 | 0.69 | C3AR1 (0.44) | CYP3A4CYP1A2CYP2D6TSHROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1598 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| US-12246098-B2 | Trans-epithelial membrane drug delivery system | BioPhysics Pharma, Inc. (US) | 2025-03-11 | — | — | US | claimed |
| US-20240216292-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2024-07-04 | — | — | US | claimed |
| US-20240108588-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2024-04-04 | — | — | US | claimed |
| US-11865217-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2024-01-09 | — | — | US | claimed |
| EP-4106816-A1 | TRANSMUCOSAL DRUG DELIVERY SYSTEM | North Atlantic Holdings LLC (US) | 2022-12-28 | — | — | EP | claimed |
| US-20220387343-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2022-12-08 | — | — | US | claimed |
| US-11446257-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2022-09-20 | — | — | US | claimed |
| EP-3856140-A1 | TRANSDERMAL DRUG DELIVERY SYSTEM | Biophysics Pharma, Inc. (US) | 2021-08-04 | — | — | EP | claimed |
| US-20200101025-A1 | Transdermal Drug Delivery System | BioPhysics Pharma, Inc. (US) | 2020-04-02 | — | — | US | claimed |
| WO-2020069013-A1 | TRANSDERMAL DRUG DELIVERY SYSTEM | BioPhysics Pharma, Inc. (US) | 2020-04-02 | — | — | WO | claimed |
| US-8354116-B2 | Bifunctional synthetic molecules | BIOCHEMICS, INC. (US) | 2013-01-15 | — | — | US | claimed |
| EP-2167104-A1 | BIFUNCTIONAL SYNTHETIC MOLECULES | BioChemics, Inc. (US) | 2010-03-31 | — | — | EP | claimed |
| WO-2008156758-A1 | BIFUNCTIONAL SYNTHETIC MOLECULES | BIOCHEMICS, INC. (US) | 2008-12-24 | — | — | WO | claimed |
| US-20080312296-A1 | Bifunctional synthetic molecules | ADEC PRIVATE EQUITY INVESTMENTS, LLC | 2008-12-18 | — | — | US | claimed |
| EP-1641446-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | Pediamed Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2004112771-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | PEDIAMED PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312296-A1 | Bifunctional synthetic molecules | PGF, VEGFA, PTGFR | OPRM1 2286/4885SLC6A2 281/4885ESR1 1012/4885 |
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | OPRM1 588/4885SLC6A2 24/4885ESR1 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.